Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy

International Journal of Urology

Volumn 20, Issue 8, 2013, Pages 744-755

  Yoshimura, Kazuhiro ^a   Uemura, Hirotsugu ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Autologous tumor cell vaccine; Dendritic cell vaccine; Genetically modified vaccine; Peptide vaccine; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CARBONATE DEHYDRATASE IX; DENDRITIC CELL VACCINE; INTERLEUKIN 2; PEPTIDE VACCINE; SURVIVIN; TELOMERASE; TUMOR CELL VACCINE;

CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DNA MODIFICATION; DRUG MEGADOSE; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VACCINE PRODUCTION;

AUTOLOGOUS TUMOR CELL VACCINE; DENDRITIC CELL VACCINE; GENETICALLY MODIFIED VACCINE; PEPTIDE VACCINE; RENAL CELL CARCINOMA;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY, ACTIVE; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 84881312003     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12147     Document Type: Review

References (84)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 1893; 5: 487-511.
2. Neidhart JA, Murphy SG, Hennick LA, Wise HA. Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer 1980; 46: 1128-1134.
3. McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 1990; 32: 62-66.
4. Sahasrabudhe DM, deKernion JB, Pontes JE etal. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J. Biol. Response Mod. 1986; 5: 581-594.
5. Finn OJ. Cancer immunology. N. Engl. J. Med. 2008; 358: 2704-2715.
6. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426.
7. Frey AB, Monu N. Signaling defects in anti-tumor T cells. Immunol. Rev. 2008; 222: 192-205.
8. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 2008; 222: 129-144.
9. Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin. Biol. Ther. 2010; 10: 1573-1586.
10. Wysocki PJ, Kazimierczak U, Suchorska W, Koltarski M, Malicki JM, Mackiewicz A. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interluekin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther. 2010; 17: 465-475.
11. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur. Urol. 2006; 50: 34-43.
12. Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee HG. Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother. 2007; 56: 117-128.
13. Frankenberger B, Regn S, Geiger C etal. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J. Urol. 2005; 23: 166-174.
14. Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev. Vaccines 2004; 3: 403-411.
15. Guida M, Colluci G. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? Ann. Oncol. 2007; 18: 149-152.
16. Kurth KH, Marquet R, Zwartendijk J, Warnaar SO. Autologous anticancer antigen preparation for specific immunotherapy in advanced renal cell carcinoma. Eur. Urol. 1987; 13: 103-109.
17. McCune CS, Schapira DV, Henshaw EC. Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 1981; 47: 1984-1987.
18. Schärfe T, Muller S, Riedmiller H etal. Immunotherapy of metastasizing renal cell carcinoma. Results of a multicentered trial. Urol. Int. 1989; 44: 1-4.
19. Galligioni E, Quaia M, Merlo A etal. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 1996; 77: 2560-2566.
20. Schwaab T, Heaney JA, Schned AR etal. A randomized Phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J. Urol. 2000; 163: 1322-1327.
21. Jocham D, Richter A, Hoffmann L etal. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomized controlled trial. Lancet 2004; 363: 594-599.
22. Repmann R, Wagner S, Richter A. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor cell lysate vaccine. Anticancer Res. 1997; 17: 2879-2882.
23. May M, Brookman-May S, Hoschke B etal. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol. Immunother. 2010; 59: 687-695.
24. Dillman R, Barth N, Vandermolen L etal. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother. Radiopharm. 2004; 19: 570-580.
25. Dudek AZ, Mescher MF, Okazaki I etal. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am. J. Clin. Oncol. 2008; 31: 173-181.
26. Doehn C, Richter A, Theodor RA etal. An adjuvant vaccination with Reniale prolongs survival in patients with RCC following radical nephrectomy: secondary analysis of a multicenter Phase-III trial. J. Urol. 2007; 177 (Suppl): 167 (Abstract 500).
27. Simons JW, Jaffee EM, Weber CE etal. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colonystimulating factor gene transfer. Cancer Res. 1997; 57: 1537-1546.
28. Antonia SJ, Seigne J, Diaz J etal. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. 2002; 167: 1995-2000.
29. Pizza G, De Vinci C, Lo Conte G etal. Allogeneic gene-modified tumor cells in metastatic kidney cancer. Report II. Folia Biol. (Praha) 2004; 50: 175-183.
30. Kübler H, Vieweg J. Vaccines in renal cell carcinoma. Semin. Oncol. 2006; 33: 614-624.
31. Wittig B, Marten A, Dorbic T etal. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical Phase I/II trial. Hum. Gene Ther. 2001; 12: 267-278.
32. Tani K, Azuma M, Nakazaki Y etal. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol. Ther. 2004; 10: 799-816.
33. Fishman M, Hunter TB, Soliman H etal. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J. Immunother. 2008; 31: 72-80.
34. Amato RJ. Vaccine therapy for renal cell carcinoma. Rev. Urol. 2003; 5: 65-71.
35. Avigan D. Dendritic cell/tumour fusions vaccine. Dev. Biol. (Basel) 2004; 116: 161-168.
36. Berntsen A, Geertsen PF, Svane IM etal. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur. Urol. 2006; 50: 34-43.
37. Höltl L, Rieser C, Papesh C etal. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. 1999; 161: 777-782.
38. Märten A, Flieger D, Renoth S etal. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/II trial. Cancer Immunol. Immunother. 2002; 51: 637-644.
39. Höltl L, Zelle-Rieser C, Gander H etal. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 2002; 8: 3369-3376.
40. Märten A, Renoth S, Heinicke T etal. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 2003; 14: 483-494.
41. Oosterwijk E, Divgi CR, Brouwers A etal. Monoclonal antibody-based therapy for renal cell carcinoma. Urol. Clin. North Am. 2003; 30: 623-631.
42. Gitlitz BJ, Belldegrun AS, Zisman A etal. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. 2003; 26: 412-419.
43. Su Z, Dannull J, Heiser A etal. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003; 63: 2127-2133.
44. Arroyo JC, Gabilondo F, Llorente L etal. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J. Clin. Immunol. 2004; 24: 86-96.
45. Pandha HS, John RJ, Hutchinson J etal. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a Phase I/II study. BJU Int. 2004; 94: 412-418.
46. Dannull J, Su Z, Rizzieri D etal. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005; 115: 3623-3633.
47. Barbuto JA, Ensina LF, Neves AR etal. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother. 2005; 54: 663-670.
48. Höltl L, Ramoner R, Zelle-Rieser C etal. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophophamide. Cancer Immunol. Immunother. 2005; 54: 663-670.
49. Wierecky J, Muller MR, Wirths S etal. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006; 66: 5910-5918.
50. Matsumoto A, Haraguchi K, Takahashi T etal. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int. J. Urol. 2007; 14: 277-283.
51. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC etal. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptidepulsed mature dendritic cells. J. Immunother. 2007; 30: 116-122.
52. Kim JH, Lee Y, Bae YS etal. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin. Immunol. 2007; 125: 257-267.
53. Wei YC, Sticca RP, Li J etal. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: a pilot study. Oncol. Rep. 2007; 18: 665-671.
54. Avigan DE, Vasir B, George DJ etal. Phase I/II study of vaccination with electrofused dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 2007; 30: 749-761.
55. Schwaab T, Schwarzer A, Wolf B etal. Clinical and immunologic effects of intranodal autologous tumor lysatedendritic cell vaccine with aldesleukin (interleukin 2) and IFN-a2a therapy in metastatic renal cell carcinoma patients. Clin. Cancer Res. 2009; 15: 4986-4992.
56. Soleimani A, Berntsen A, Svanet IM, Pederson AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand. J. Immunol. 2009; 70: 481-489.
57. Van Poppel H, Joniau S, Van Gool S. Vaccine therapy in patients with renal cell carcinoma. Eur. Urol. 2009; 55: 1333-1344.
58. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I etal. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase I study. J. Immunother. 2002; 25: 500-508.
59. Frankenberger B, Regn S, Geiger C etal. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and moncyte-derived dendritic cells. World J. Urol. 2005; 23: 166-174.
60. Uemura H, Fujimoto K, Tanaka M etal. A Phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin. Cancer Res. 2006; 12: 1768-1775.
61. Iiyama T, Udaka K, Takeda S etal. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol. Immunol. 2007; 51: 519-530.
62. Suekane S, Nishitani M, Noguchi M etal. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci. 2007; 98: 1965-1968.
63. Patel PM, Sim S, O'Donnell DO etal. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur. J. Cancer 2008; 44: 216-223.
64. Jonasch E, Wood C, Tamboli P etal. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br. J. Cancer 2008; 98: 1336-1341.
65. Amato RJ, Hawkins RE, Kaufman HL etal. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled Phase III study. Clin. Cancer Res. 2010; 22: 5539-5547.
66. Rahma OE, Ashtar E, Ibrahim R etal. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J. Transl. Med. 2010; 8: 8-16.
67. Walter S, Weinschenk T, Stenzl A etal. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012; 18: 1254-1261.
68. Wood C, Srivastava P, Bukowski R etal. An adjuvant autologous therapeutic vaccine (HSPCC-96; vitespen) versus observation alone for patients at high-risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomized Phase III trial. Lancet 2008; 372: 145-154.
69. Liao SY, Brewer C, Zavada J etal. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am. J. Pathol. 1994; 145: 598-609.
70. Turner JR, Odze RD, Crum CP etal. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum. Pathol. 1997; 28: 740-744.
71. Saarnio J, Parkkila S, Parkkila AK etal. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol. 1998; 153: 279-285.
72. Saarnio J, Parkkila S, Parkkila AK etal. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J. Histochem. Cytochem. 1998; 46: 497-504.
73. Swinson DE, Jones JL, Richardson D etal. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J. Clin. Oncol. 2003; 21: 473-482.
74. Gouttefangeas C, Stenzl A, Stevanović S, Rammensee HG. Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother. 2007; 56: 117-128.
75. Elkord E, Shablak A, Stern PL, Hawkins RE. 5T4 as a target for immunotherapy in renal cell carcinoma. Expert Rev. Anticancer Ther. 2009; 9: 1705-1709.
76. Amato RJ, Shingler W, Naylor S etal. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a Phase II trial. Clin. Cancer Res. 2008; 14: 7504-7510.
77. Kaufmann HL, Taback B, Sherman W etal. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J. Transl. Med. 2009; 7: 2-12.
78. Amato RJ, Shingler W, Goonewardena M etal. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFNalpha): a Phase 2 trial. J. Immunother. 2009; 32: 765-772.
79. Hawkins RE, McDermott C, Shablak A etal. Vaccination of patients with metastatic renal cell cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J. Immunother. 2009; 32: 424-429.
80. Kim DW, Krishnamurthy V, Bines SD, Kaufman HL. Trovax, a recombinant modified vaccinia Ankara virus encoding 5T4. Lessons learned and future development. Hum. Vaccin. 2010; 10: 1-8.
81. Dunn GP, Bruce AT, Ikeda H etal. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002; 3: 991-998.
82. Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim. Biophys. Acta 2007; 1776: 108-123.
83. Parmiani G, Castelli C, Dalerba P etal. Cancer immunotherapy with peptide-based vaccines: what have we achieved? where are we going?. J. Natl. Cancer Inst. 2002; 94: 805-818.
84. Uemura H, De Velasco MA. Tumor vaccines in renal cell carcinoma. World J. Urol. 2008; 26: 147-154.